ARTICLES

What determines whether a breakthrough therapy becomes a commercial success? In this Citeline In Vivo podcast, Harris Kaplan joins former Kite Pharma executive Diane Parks and CAR-T patient Jim Haag to discuss the launch of Yescarta and the critical role that stakeholder adoption, market access, and real-world implementation play in translating scientific innovation into lasting impact.

The decisions that shape commercial success are increasingly being made long before launch. As the Inflation Reduction Act continues to influence pricing, access, and reimbursement dynamics, companies must consider how evidence generation, differentiation, and value communication fit into their development strategy from the outset. In FirstWord's ExpertViews report, The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing, Harris Kaplan shares his perspective a

KOL enthusiasm can signal early promise, but it rarely tells the full story. Harris Kaplan examines why expert advocacy often fails to translate into market adoption—and what life sciences teams should evaluate instead.

Innovation in life sciences has always involved uncertainty. Today, however, regulatory unpredictability is becoming a growing driver of risk, influencing not only approval pathways but also real world confidence in new therapies.

Phase III clinical protocols do more than satisfy regulators. They determine what a product can claim, how it will be valued, and whether it can truly compete at launch.